Compare NUTX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | PHAT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 894.0M |
| IPO Year | 2009 | 2019 |
| Metric | NUTX | PHAT |
|---|---|---|
| Price | $94.00 | $10.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $252.50 | $19.50 |
| AVG Volume (30 Days) | 162.0K | ★ 994.9K |
| Earning Date | 06-15-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.93 | ★ 42.72 |
| EPS | ★ 10.48 | N/A |
| Revenue | ★ $875,257,000.00 | $175,110,000.00 |
| Revenue This Year | $18.71 | $91.62 |
| Revenue Next Year | $2.79 | $59.82 |
| P/E Ratio | $9.25 | ★ N/A |
| Revenue Growth | 82.36 | ★ 216.93 |
| 52 Week Low | $45.88 | $2.21 |
| 52 Week High | $193.07 | $18.31 |
| Indicator | NUTX | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 41.75 |
| Support Level | $81.70 | $10.65 |
| Resistance Level | $110.29 | $11.19 |
| Average True Range (ATR) | 8.37 | 0.77 |
| MACD | 0.33 | 0.02 |
| Stochastic Oscillator | 26.41 | 20.07 |
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.